Key Points Lilly's pipeline is packed with metabolic health programs. Its commercialized metabolic health medicines are big earners. It's also buying assets and businesses at a fast pace. 10 stocks we like better than Eli Lilly › There's no rule that says a leading pharma stock can't go down. On that note, shares of Eli Lilly (NYSE: LLY) are still down by 7% from their recent high set in mid-August, even though its moneymaker metabolic medicines had powered 48% revenue growth in the second quarter. Some investors seem to be afraid that the company's willingness to sell those drugs at competitive prices will erode its margins.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.